SMIC selected in “Mainland Enterprises Listed in Hong Kong Ranking Award”

SHANGHAI, Aug. 29, 2014 /PRNewswire/ — Semiconductor Manufacturing International Corporations (“SMIC”; NYSE: SMI; SEHK: 981) the largest and most advanced foundry in Mainland China, announced today, it was selected by Hong Kong Yazhou Zhoukan Limited in the Fourth Mainland Enterprises Listed in Hong Kong Ranking Award, and won the High-Tech Enterprise Award due to its exceptional business operations and outstanding performance.

Yazhou Zhoukan Limited was founded in 1987 in Hong Kong, covering matters on economics, political and social culture, which caught the attention of the Chinese worldwide. The Mainland Enterprises Listed in Hong Kong Ranking Award selects Mainland Enterprises listed in Hong Kong that has the best performance and is recognized by the market. Yazhou Zhoukan Limited’s research department makes its decisions on the rankings based on audited data from the companies. To pick out the best performing companies from each industry, the market value, turnover and growth, net profit and net profit growth, total assets, as well as level of awareness and influence in the international capital market were all examined. SMIC has shown excellent financial performance such as 9 quarters of consecutive profit, gross profit margin, and net income. Additionally, in recent years, growth rate far exceeded industry standards, and corporate social responsibility has been fulfilled by actively carrying out environmental protection and charity work, to get into the final list and win the High-Tech Enterprise Award.

Dr. Tzu-Yin Chiu, SMIC’s Chief Executive Officer and Executive Director expressed his gratitude by saying “It is an honor that SMIC has been chosen for this year’s Mainland Enterprises Listed in Hong Kong Ranking Award by Yazhou Zhoukan Limited. The award reflects Hong Kong’s market and financial media recognition for SMIC. In the future, SMIC will continue to improve its corporate governance and profitability, as well as work towards becoming a world-class manufacturer of integrated circuits and a high-quality listed company, to create greater value for our shareholders and the society.”

About SMIC

Semiconductor Manufacturing International Corporation (“SMIC”; NYSE: SMI; SEHK: 981) is one of the leading integrated circuit wafer manufacturer in the world and the largest and most advanced wafer manufacturer in mainland China. SMIC provides integrated circuit (IC) foundry and technology services at 0.35-micron to 28-nanometer. Headquartered in Shanghai, China, SMIC has a 300mm wafer fabrication facility (fab) and a 200mm mega-fab in Shanghai; a 300mm mega-fab in Beijing and a majority owned 300mm fab for advance nodes under development; a 200mm fab in Tianjin; and a 200mm fab project under development in Shenzhen. SMIC also has marketing and customer service offices in the U.S., Europe, Japan, and Taiwan, and a representative office in Hong Kong. For more information, please visit www.smics.com.

Safe Harbor Statements

(Under the Private Securities Litigation Reform Act of 1995)

This document contains, in addition to historical information, “forward-looking statements” within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on SMIC’s current assumptions, expectations and projections about future events. SMIC uses words like “believe,” “anticipate,” “intend,” “estimate,” “expect,” “project” and similar expressions to identify forward looking statements, although not all forward-looking statements contain these words. These forward-looking statements are necessarily estimates reflecting the best judgment of SMIC’s senior management and involve significant risks, both known and unknown, uncertainties and other factors that may cause SMIC’s actual performance, financial condition or results of operations to be materially different from those suggested by the forward-looking statements including, among others, risks associated with cyclicality and market conditions in the semiconductor industry, intense competition, timely wafer acceptance by SMIC’s customers, timely introduction of new technologies, SMIC’s ability to ramp new products into volume, supply and demand for semiconductor foundry services, industry overcapacity, shortages in equipment, components and raw materials, availability of manufacturing capacity, financial stability in end markets and intensive intellectual property litigation in high tech industry.

In addition to the information contained in this document, you should also consider the information contained in our other filings with the SEC, including our annual report on Form 20-F filed with the SEC on April 14, 2014, especially in the “Risk Factors” section and such other documents that we may file with the SEC or SEHK from time to time, including on Form 6-K. Other unknown or unpredictable factors also could have material adverse effects on our future results, performance or achievements. In light of these risks, uncertainties, assumptions and factors, the forward-looking events discussed in this document may not occur. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date stated or, if no date is stated, as of the date of this document.

SMIC Contact Information:

English Media
Michael Cheung
Tel: +86-21-3861-0000 x16812
Email: Michael_Cheung@smics.com

Chinese Media
Angela Miao
Tel: +86-21-3861-0000 x10088
Email: Angela_Miao@smics.com

Datawatch Appoints John Judge as Chief Revenue Officer

CHELMSFORD, Mass., Aug. 29, 2014 /PRNewswire/ — Datawatch Corporation (NASDAQ: DWCH), a leading global provider of visual data discovery solutions, announced today the appointment of John P. Judge as chief revenue officer, senior vice president of Worldwide Sales. Mr. Judge was most recently the senior vice president, Americas Enterprise Sales for Iron Mountain Corporation, a company with revenues of more than $3 billion, where he was responsible for nearly one third of the company’s revenue. Prior to joining Iron Mountain, Mr. Judge held senior sales role at Novell, SilverStream Software, and Honeywell. 

Logo – http://photos.prnewswire.com/prnh/20121015/NE92833LOGO

At Datawatch, Mr. Judge will be responsible for all sales, services and partner operations globally. Mr. Judge holds a bachelor of science in business administration and marketing from the University of Maine.

“John’s appointment demonstrates to our customers, partners, shareholders and employees alike that Datawatch is committed to accelerating long-term growth,” said Michael Morrison, president and chief executive officer of Datawatch. “With John’s leadership, our sales organization will bring a value-based selling approach to the rapidly growing visual data discovery market, create a clearer articulation of our approach to vertical industries, deepen our engagement with channel partners, and increase our contribution to client success. We are thrilled to add another world-class executive to the Datawatch management team.”

“To me, it’s all about the customer experience,” said Mr. Judge. “Datawatch is exciting, because I believe we have the opportunity to challenge assumptions with transformational technology, bring a broader point of view to how data visualization can speed up our customers’ businesses, and foster a client facing experience that will create true brand differentiation in the market and expand our business significantly.”

About Datawatch Corporation

Datawatch Corporation (NASDAQ-CM: DWCH) provides visual data discovery software that optimizes any data – regardless of its variety, volume, or velocity – delivering next generation analytics to reveal valuable insights for improving business. Its unique ability to integrate structured, unstructured, and semi-structured sources like reports, PDF files and EDI streams with real-time streaming data into visually rich analytic applications allows users to dynamically discover key factors that impact any operational aspect of their business. This ability to perform visual discovery against any data sets Datawatch apart in the big data and visualization markets. Organizations of every size, worldwide use Datawatch products, including 99 of the Fortune 100. Datawatch is headquartered in Chelmsford, Massachusetts with offices in New York, London, Munich, Stockholm, Singapore, Sydney and Manila, and with partners and customers in more than 100 countries worldwide. See the Whole Story for yourself by downloading the free trial at www.datawatch.com/free-trial.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any such statements, including but not limited to those relating to results of operations, contained herein are based on current expectations, but are subject to a number of risks and uncertainties that may cause actual results to differ materially from expectations. The factors that could cause actual future results to differ materially from current expectations include the following: risks associated with the continuing weak global economy; risks associated with fluctuations in quarterly operating results due, among other factors, to the size and timing of large customer orders; risks associated with acquisitions, including the recent acquisition of intellectual property from Math Strategies and the acquisition of Panopticon; the volatility of Datawatch’s stock price; limitations on the effectiveness of internal controls; rapid technological change; Datawatch’s dependence on the introduction of new products and possible delays in those introductions; competition in the software industry generally, and in the markets for next generation analytics in particular; Datawatch’s dependence on its principal products, proprietary software technology and software licensed from third parties; risks associated with international sales and operations; risks associated with indirect distribution channels and co-marketing arrangements, many of which were only recently established; the adequacy of Datawatch’s sales returns reserve; risks associated with a subscription sales model; Datawatch’s dependence on its ability to hire and retain skilled personnel; disruption or failure of Datawatch’s technology systems that may result from a natural disaster, cyber-attack or other catastrophic event; and uncertainty and additional costs that may result from evolving regulation of corporate governance and public disclosure. Further information on factors that could cause actual results to differ from those anticipated is detailed in various publicly-available documents, which include, but are not limited to, filings made by Datawatch from time to time with the Securities and Exchange Commission, including but not limited to, those appearing in the Company’s Annual Report on Form 10-K for the year ended September 30, 2013 and Forms 10-Q for the quarters ended December 31, 2013, March 31, 2014 and June 30, 2014. Any forward-looking statements should be considered in light of those factors.

Investor Contact:
Datawatch Investor Relations 
investor@datawatch.com
Phone: (978) 441-2200 ext. 8323

Media Contact: 
Sarah Bernardi
Datawatch Corporation
Sarah_Bernardi@datawatch.com
Phone: (978) 441-2200 ext. 8387
Twitter: @datawatch

© 2014 Datawatch Corporation. Datawatch and the Datawatch logo are trademarks or registered trademarks of Datawatch Corporation in the United States and/or other countries. All other names are trademarks or registered trademarks of their respective companies.

China Cord Blood Corporation Reports First Quarter Fiscal 2015 Financial Results

1Q15 Added 15,548 New Subscribers

1Q15 Revenue Up 19.1% YOY to RMB153.3 Million ($24.7 Million)

1Q15 Operating Income Up 31.1%YOY to RMB60.2 Million ($9.7 Million)

Conference Call to be Held August 29, 2014 at 8:00 a.m. ET

HONG KONG, Aug. 29, 2014 /PRNewswire/ — China Cord Blood Corporation (NYSE: CO) (“CCBC” or the “Company”), China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced its preliminary unaudited financial results for the first quarter of fiscal year 2015 ended June 30, 2014.

First Quarter of Fiscal 2015 Highlights

  • Revenues for the first quarter of fiscal 2015 increased to RMB153.3 million ($24.7 million) from RMB128.7 million in the prior year period.
  • 15,548 new subscribers were added, resulting in an accumulated subscriber base of 392,171.
  • Gross profit increased to RMB123.6 million ($19.9 million) from RMB104.2 million in the prior year period.
  • Gross margin was 80.6%, compared to 81.0% in the prior year period.
  • Operating income increased to RMB60.2 million ($9.7 million), from RMB45.9 million in the prior year period, despite an RMB2.8 million increase in depreciation expense.
  • Interest expense increased to RMB24.9 million ($4.0 million), compared to RMB14.8 million in the prior year period, due to less interest expense capitalization.
  • Net income attributable to the Company’s shareholders was RMB29.7 million ($4.8 million), compared to RMB32.9 million in the prior year period.
  • Operating cash flow for the quarter was RMB124.6 million ($20.1 million).

“We began fiscal 2015 with another solid quarter, adding 15,548 new subscribers which represented a modest year-over-year increase,” stated Ms. Ting Zheng, Chief Executive Officer of CCBC. “Through the implementation of sound marketing strategies that focus on service quality and premium branding, we continued to seize opportunities in the high-end segment of the market. As the majority of our new subscribers selected the one-time upfront payment option, our cash-flow generation remained robust and consistent.”

Ms. Zheng further commented, “With our new facilities in Guangdong and Zhejiang largely completed, we are working through the final stages of their development to ensure they are fully operational as soon as possible. The new processing and storage capacity will effectively resolve our processing bottleneck in Zhejiang and allow us to gradually scale up our operations in this under-penetrated region. The additional capacity will also allow us to further develop and penetrate the Guangdong market, the area in which the majority of our new subscribers in the first quarter are located.”

Summary – First Quarter Ended June 30, 2013 and 2014

Three Months Ended
June 30,

2013

2014

(in thousands)

RMB

RMB

US$

Revenues

128,721

153,331

24,716

Gross Profit

104,229

123,555

19,916

Operating Income

45,880

60,167

9,698

Net Income Attributable to the Company’s Shareholders

32,906

29,736

4,793

 

Earnings per Ordinary Shares

– Basic[1] and Diluted (RMB/US$)

0.40

0.37

0.06

Revenue Breakdown (%)

Processing Fees

69.5%

69.2%

Storage Fees

30.5%

30.8%

New Subscribers (persons)

15,260

15,548

Total Accumulated Subscribers (persons)

327,242

392,171

[1] The terms of the convertible notes issued to KKR China Healthcare Investment Limited (“KKR”) and Golden Meditech Holdings Limited (“Golden Meditech”) provide each party with the ability to participate in any excess cash dividend. Therefore, the calculation of basic EPS has taken into consideration the effect of such participating rights of RMB0.04 ($0.01) for the three months ended June 30, 2014.

Summary – Selected Cash Flow Statement Items

Three Months Ended

June 30, 2014

(in thousands)

RMB

US$

Net cash provided by operating activities

124,643

20,091

Net cash used in investing activities

(18,397)

(2,965)

Net cash used in financing activities

First Quarter of Fiscal 2015 Financial Results

REVENUES. Revenues increased by 19.1% to RMB153.3 million ($24.7 million) in the first quarter of fiscal 2015 from RMB128.7 million in the prior year period. The increase in revenues resulted from solid growth in both processing and storage revenue.

Revenues generated from storage fees increased by 20.1% to RMB47.2 million ($7.6 million), from RMB39.3 million in the prior year period. The increase was mainly due to the steady growth of the Company’s accumulated subscriber base, which has expanded to 392,171 as of the end of June 2014. Revenues generated from storage fees as a percentage of total revenues edged up to approximately 30.8%, from 30.5% in the prior year period.

The difference in processing fees between the first quarter of fiscal 2015 and 2014, combined with the year-over-year growth in subscriber number, contributed to the increase in revenues generated from processing fees to RMB106.1 million ($17.1 million) from RMB89.4 million in the prior year period. As a percentage of total revenues, revenues from processing fees accounted for 69.2%, compared to 69.5% in the prior year period.

GROSS PROFIT. Gross profit for the first quarter of fiscal 2015 increased by 18.5% to RMB123.6 million ($19.9 million). Gross margin decreased slightly to 80.6% from 81.0% in the prior year period primarily due to increased material costs.

OPERATING INCOME. Operating income for the first quarter of fiscal 2015 increased to RMB60.2 million ($9.7 million), resulting in an operating margin of 39.2%, which is a 3.6% improvement from 35.6% in the prior year period. Depreciation and amortization expenses for the first quarter were RMB11.4 million ($1.8 million), compared to RMB8.6 million in the prior year period.

Research and Development Expenses. Research and development expenses remained stable at RMB2.5 million ($0.4 million).

Sales and Marketing Expenses. During the quarter, the Company’s sales and marketing expenses increased to RMB31.7 million ($5.1 million) from RMB28.4 million in the prior year period. However, as a percentage of revenues, sales and marketing expenses decreased to 20.7% from 22.1%. The improvement is a result of the Company’s focus on resource allocation and sales efficiency while further penetrating markets across the Company’s operating regions. While the new facilities in Zhejiang are expected to be operational in the near future, management continues to carefully plan and execute its marketing strategy and ensure that expenses are kept in check in that region.

General and Administrative Expenses. General and administrative expenses increased to RMB29.1 million ($4.7 million) from RMB27.4 million in the prior year period. This increase was primarily due to increased depreciation expenses and administrative overhead stemming from preparation for the full commercial launch of the Company’s new facilities. However as a percentage of revenues, G&A expenses decreased to 19.0% from 21.3%, as the overall increase in revenues exceeded the rise in depreciation and administrative expenses.

OTHER INCOME AND EXPENSES

Interest Expense. Interest expense incurred in the three months ended June 30, 2014 amounted to RMB24.9 million ($4.0 million), which primarily relates to the Company’s outstanding convertible notes. For the prior year period, interest expense was RMB14.8 million due to the RMB8.5 million capitalization of interest expense for the construction of the Company’s new facilities in Zhejiang and Guangdong.

Other. For the first quarter of fiscal 2015, the Company recorded dividend income of RMB1.2 million ($0.2 million), which was derived from the Company’s equity investment in Cordlife Group Limited (“Cordlife”). During the first quarter of fiscal 2014, the Company received dividend income of RMB8.7 million from its equity investments in both the Shandong Cord Blood Bank and Cordlife.  

NET INCOME ATTRIBUTABLE TO THE COMPANY’S SHAREHOLDERS. Profit before tax for the first quarter of fiscal 2015 decreased by 6.5% to RMB41.5 million ($6.7 million). The Company’s improved operating income was offset by the increase in interest expense and decrease in dividend income. As a result, net income attributable to the Company’s shareholders for the first quarter of fiscal 2015 decreased by 9.6% to RMB29.7 million ($4.8 million).

EARNINGS PER SHARE. The terms of the convertible notes issued to KKR and Golden Meditech provide each party with the ability to participate in any Excess Cash Dividend[2]. Therefore, the calculation of basic and diluted EPS has taken into consideration the effect of such participating rights of RMB0.04 ($0.01) for the first quarter of fiscal 2015. Basic and diluted earnings per ordinary share for the first quarter of fiscal 2015 were RMB0.37 ($0.06).

[2] “Excess Cash Dividend” means any cash dividend to holders of shares that, together with all other cash dividends previously paid to holders of shares in the same financial year, exceeds, on a per share basis, an amount equal to the interest that has accrued and shall accrue at 7% in such financial year divided by the number of shares into which the note is convertible at the conversion price then in effect on the relevant record date.

LIQUIDITY. As of June 30, 2014, the Company had cash and cash equivalents of RMB1,989.5 million ($320.7 million) compared to RMB1,882.9 million as of March 31, 2014. The Company had total debt of RMB848.0 million ($136.7 million) as of June 30, 2014. Operating cash inflow for the first quarter of fiscal 2015 amounted to RMB124.6 million ($20.1 million).

Conference Call

The Company will host a conference call at 8:00 a.m. ET on Friday, August 29, 2014 to discuss its financial performance and give a brief overview of recent developments, followed by a question and answer session. Interested parties may access the audio webcast through the Company’s IR website at http://ir.chinacordbloodcorp.com. A replay of the webcast will be accessible two hours after the presentation and available for three weeks at the same URL link above. Listeners may also access the call by dialing 1-631-514-2526 or 1-855-298-3404 for US callers or +852-5808-3202 for Hong Kong callers, access code: 1856118.

About China Cord Blood Corporation

China Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses. Under current PRC government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and only seven licenses have been authorized as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. For more information, please visit our website at http://www.chinacordbloodcorp.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or the Company’s future financial performance. The Company has attempted to identify forward-looking statements by terminology including “anticipates”, “believes”, “expects”, “can”, “continue”, “could”, “estimates”, “intends”, “may”, “plans”, “potential”, “predict”, “should” or “will” or the negative of these terms or other comparable terminology. These statements are only predictions; uncertainties and other factors may cause the Company’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The information in this press release is not intended to project future performance of the Company. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company does not guarantee future results, levels of activity, performance or achievements. The Company expectations are as of the date this press release is issued, and the Company does not intend to update any of the forward-looking statements after the date this press release is issued to conform these statements to actual results, unless required by law.

The forward-looking statements included in this press release are subject to risks, uncertainties and assumptions about the Company’s businesses and business environments. These statements reflect the Company’s current views with respect to future events and are not a guarantee of future performance. Actual results of the Company’s operations may differ materially from information contained in the forward-looking statements as a result of risk factors some of which include, among other things: continued compliance with government regulations regarding cord blood banking in the People’s Republic of China, or PRC and any other jurisdiction in which the Company conducts its operations; changing legislation or regulatory environments (including revisions to China’s One Child Policy) in the PRC and any other jurisdiction in which the Company conducts its operations; the acceptance by subscribers of the Company’s different pricing and payment options and reaction to the introduction of the Company’s premium-quality pricing strategy; demographic trends in the regions of the PRC in which the Company is the exclusive licensed cord blood banking operator; labor and personnel relations; the existence of a significant shareholder able to influence and direct the corporate policies of the Company; credit risks affecting the Company’s revenue and profitability; changes in the healthcare industry, including those which may result in the use of stem cell therapies becoming redundant or obsolete; the Company’s ability to effectively manage its growth, including implementing effective controls and procedures and attracting and retaining key management and personnel; changing interpretations of generally accepted accounting principles; the availability of capital resources, including in the form of capital markets financing opportunities, in light of industry developments affecting issuers that have pursued a “reverse merger” with an operating company based in China, as well as general economic conditions; compliance with restrictive debt covenants under our senior convertible notes; and other relevant risks detailed in the Company’s filings with the Securities and Exchange Commission in the United States.

This announcement contains translations of certain Renminbi amounts into U.S. dollars at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from Renminbi to U.S. dollars as of and for the periods ending June 30, 2014 were made at the noon buying rate of RMB6.2036 to $1.00 on June 30, 2014 in the City of New York for cable transfers in Renminbi per U.S. dollar as certified for customs purposes by the Federal Reserve Bank of New York. China Cord Blood Corporation makes no representation that the Renminbi or U.S. dollar amounts referred to in this press release could have been or could be converted into U.S. dollars or Renminbi, at any particular rate or at all.

For more information, please contact:

China Cord Blood Corporation
Investor Relations Department
Tel: (+852) 3605-8180
Email: ir@chinacordbloodcorp.com

ICR, Inc.
Mr. William Zima
Tel: (+86) 10-6583-7511
U.S. Tel: (646) 405-5185
Email: William.Zima@icrinc.com

EXHIBIT 1

CHINA CORD BLOOD CORPORATION

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

As of March 31 and June 30, 2014

March 31,

June 30,

2014

2014

RMB

    RMB

  US$

(in thousands except share data)

ASSETS

Current assets

Cash and cash equivalents

1,882,901

1,989,506

320,702

Accounts receivable, less allowance for doubtful accounts

(March 31, 2014: RMB20,322; June 30, 2014: RMB22,145)

95,273

101,900

16,426

Inventories

31,583

29,008

4,677

Prepaid expenses and other receivables

37,010

27,339

4,407

Debt issuance costs

3,616

3,615

583

Deferred tax assets

7,664

7,948

1,281

Total current assets

2,058,047

2,159,316

348,076

Property, plant and equipment, net

626,632

618,553

99,709

Non-current prepayments

208,894

214,825

34,629

Non-current accounts receivable, less allowance for doubtful
accounts (March 31, 2014: RMB42,703; June 30, 2014:
RMB43,722)

225,496

220,924

35,612

Inventories

48,385

51,256

8,262

Intangible assets, net

120,549

119,394

19,246

Available-for-sale equity securities

144,247

148,711

23,972

Other investment

189,129

189,129

30,487

Debt issuance costs

7,854

6,951

1,120

Deferred tax assets

1,789

1,893

305

Total assets

3,631,022

3,730,952

601,418

LIABILITIES

Current liabilities

Bank loan

60,000

60,000

9,672

Accounts payable

10,422

14,957

2,411

Accrued expenses and other payables

102,559

68,567

11,053

Deferred revenue

196,432

198,717

32,033

Amounts due to related parties

21,453

16,820

2,711

Income tax payable

2,571

1,525

246

Deferred tax liabilities

3,900

5,200

838

Total current liabilities

397,337

365,786

58,964

Convertible notes

777,753

787,988

127,021

Non-current deferred revenue

823,921

897,363

144,652

Other non-current liabilities

164,077

177,551

28,621

Deferred tax liabilities

27,938

27,639

4,455

Total liabilities

2,191,026

2,256,327

363,713

EQUITY

Shareholders’ equity of China Cord Blood Corporation

Ordinary shares

– US$0.0001 par value, 250,000,000 shares authorized, 73,140,147
shares issued and 73,003,248 shares outstanding as of March 31 and
June 30, 2014, respectively

50

50

8

Additional paid-in capital

798,221

798,221

128,671

Treasury stock, at cost (March 31 and June 30, 2014: 136,899 shares,
respectively)

 

(2,815)

 

(2,815)

 

(454)

Accumulated other comprehensive income

84,263

89,298

14,395

Retained earnings

555,323

585,059

94,309

Total equity attributable to China Cord Blood Corporation

1,435,042

1,469,813

236,929

Noncontrolling interests

4,954

4,812

776

Total equity

1,439,996

1,474,625

237,705

Total liabilities and equity

3,631,022

3,730,952

601,418

EXHIBIT 2

CHINA CORD BLOOD CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

For the Three Months ended June 30, 2013 and 2014

Three months ended June 30,

2013

2014

RMB

RMB

US$

(in thousands except share data)

Revenues

128,721

153,331

24,716

Direct costs

(24,492)

(29,776)

(4,800)

Gross profit

104,229

123,555

19,916

Operating expenses

Research and development

(2,523)

(2,499)

(403)

Sales and marketing

(28,424)

(31,743)

(5,117)

General and administrative

(27,402)

(29,146)

(4,698)

Total operating expenses

(58,349)

(63,388)

(10,218)

Operating income

45,880

60,167

9,698

Other expense, net

Interest income

4,182

4,266

688

Interest expense

(14,758)

(24,895)

(4,013)

Exchange (loss)/gain

(124)

180

29

Dividend income

8,722

1,196

193

Others

530

617

99

Total other expense, net

(1,448)

(18,636)

(3,004)

Income before income tax

44,432

41,531

6,694

Income tax expense

(11,373)

(11,937)

(1,924)

Net income

33,059

29,594

4,770

Net income attributable to non-controlling interests

(153)

142

23

Net income attributable to China Cord Blood
  
Corporation’s shareholders

32,906

29,736

4,793

Net income per share:

Attributable to ordinary shares

– Basic

0.40

0.37

0.06

– Diluted

0.40

0.37

0.06

Other comprehensive income

– Net effect of foreign currency translation, net of nil tax

6,805

529

85

– Net unrealized gain in available-for-sale equity
securities, net of nil tax

24,338

4,506

726

Comprehensive income

64,202

34,629

5,581

Comprehensive income attributable to non-controlling
interests

(153)

142

23

Comprehensive income attributable to China Cord
Blood Corporation’s shareholders

64,049

34,771

5,604

Frost & Sullivan: Colombian and Peruvian Contact Center Outsourcers Focus on the Americas

— Spain’s dwindling contribution to the offshoring segment has compelled market participants to alter their geographical strategy

BUENOS AIRES, Argentina, Aug. 29, 2014 /PRNewswire/ — A mix of quality and competitive costs ensured that the contact center outsourcing services markets in Colombia and Peru were among the most dynamic markets in Latin America up until last year. Since 2013, the market has lost some of its pace as competitive pressures have intensified with the entry of many participants. To navigate the transformed landscape, contact center outsourcing service providers will have to keep up with new entrants’ world-class practices, which have elevated quality standards in both countries.

Sebastian Menutti, ICT Industry Analyst, Frost & Sullivan

Sebastian Menutti, ICT Industry Analyst, Frost & Sullivan

Photo – http://photos.prnewswire.com/prnh/20140828/141113

New analysis from Frost & Sullivan, Colombia and Peru Contact Center Outsourcing Services Markets 2014, finds that the Colombian market earned $1,045.6 million in 2013 and estimates this to reach $2,206.2 million in 2020. Peru’s market revenues stood at $385.4 million in 2013 and this is projected to go up to $647.3 million in 2020.

“In the Colombian contact center outsourcing services market, domestic business still accounts for more than 70 percent of the revenues. However, revenues from the offshoring segment are growing at a faster rate than those from domestic business as a result of multiple deals with the United States,” said Frost & Sullivan Information & Communication Technologies Industry Analyst Sebastian Menutti. “Meanwhile, in the Peruvian market, nearshoring from South American countries such as Argentina and Chile is bringing in new business.”

In 2013, Spain once again emerged as the main destination that offshored work to contact center outsourcing service providers in Colombia and Peru. Nevertheless, offshoring revenues generated from Spain in 2013 decreased in Peru and suffered from a growth slowdown in Colombia, owing to the recent Spanish economic crisis. 

“Consequently, several Colombian and Peruvian contact center outsourcers were forced to refocus their business models and direct their commercial efforts either to domestic businesses in the high-performing local economies or businesses in other countries likely to avail offshoring services,” noted Menutti. “Prime targets for developing the offshoring segment have been South and North America, which are expected to become the dominant regions driving this segment by 2020.”

For more information on this study, please email Francesca Valente, Corporate Communications, at francesca.valente@frost.com.

Colombia and Peru Contact Center Outsourcing Services Markets 2014 is part of the Contact Centers & CRM (http://www.contactcenter.frost.com) Growth Partnership Service program. Frost & Sullivan’s related studies include: Latin American Contact Center Systems Market 2014, Brazilian BPO and Contact Center Outsourcing Services Market 2014, Argentine and Chilean Contact Center Outsourcing Services Markets, and Mexico and Central America and the Caribbean Contact Center Outsourcing Services Markets. All studies included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion

Join Us:           Join our community

Subscribe:       Newsletter on “the next big thing”

Register:         Gain access to visionary innovation

Colombia and Peru Contact Center Outsourcing Services Markets 2014
NDB7-76

Contact:
Francesca Valente
Corporate Communications – Latin America
P: +54 11 4777 5300
F: +54 11 4777 5300
E: francesca.valente@frost.com

http://www.frost.com

Photo – http://photos.prnasia.com/prnh/20140829/8521404878

SEA-US: Global Consortium to Build Cable System Connecting Indonesia, the Philippines, and the United States

MANILA, Philippines, Aug. 29, 2014 /PRNewswire/ — A consortium of seven global telecommunications companies agreed today to cooperate in the construction and operation of a new submarine cable system that directly connects Southeast Asia and the United States with NEC Corporation as the system supplier. The Southeast Asia – United States “SEA-US” consortium consists of PT. Telekomunikasi Indonesia International (Telin), Globe Telecom, RAM Telecom International (RTI), Hawaiian Telcom, Teleguam Holdings (GTA), GTI Corporation (a member of the Globe Telecom group of companies) and Telkom USA.

“The SEA-US project is connected seamlessly with Telkom’s Domestic Backbone, and the cable will provide unmatched latency from Indonesia to the United States,” said Syarif Syarial Ahmad, President Director of Telin. “The project will also support Indonesia’s strong economic growth and its government’s Master Plan for Acceleration and Expansion of Indonesia’s Economic Development (MP3EI). We began pursuing SEA-US in 2013 and are very proud to be a part of this historic project that marks the first gateway from the east part of Indonesia to the world.”

In addition, Gil Genio, Chief Operating Officer for International and Business Markets of Globe Telecom, stated, “Our country has become the preferred destination for the outsourcing and offshoring industry, including major call centers, business process outsourcing providers, global financial institutions and a host of other multinationals that require very large bandwidth. We have also seen the explosion of the mobile Internet, enabling a new lifestyle for our mobile customers and businesses. The SEA-US project will enable Globe to meet tomorrow’s bandwidth needs, and is part of our effort to provide a great customer experience on their mobile and other devices, as well as add even more diverse options for companies to connect to the U.S.”

Russ Matulich, Chief Executive Officer of RTI, continued, “The SEA-US Cable will provide much needed Asia-US connectivity and will be the fastest cable connecting Southeast Asia with the United States. It provides essential route diversity from the North Pacific and taps into to the strong economic growth of more than 1.5 billion businesses and consumers who are internet savvy and data hungry.”

Guam is a strategic location in the Pacific which allows GTA to successfully connect the Asia Pacific region to the United States. GTA’s expansive and redundant network enables secure interconnectivity to other cables, increasing Guam’s importance to future cable builds,” said Robert Haulbrook, CEO and President of GTA.

Eric Yeaman, President and Chief Executive Officer of Hawaiian Telcom, said that “Hawaiian Telcom’s participation in the SEA-US project strengthens Hawaii’s role as a key strategic hub for traffic diversity and redundancy between the US and Asia. Additionally, investing in the SEA-US system will allow Hawaiian Telcom to efficiently meet its internal long-term Trans-Pacific capacity needs, as our customers increasing demand for bandwidth continues to grow.”

The SEA-US submarine cable system links the five areas and territories of Manado (Indonesia), Davao (Philippines), Piti (Guam), Oahu (Hawaii, United States) and Los Angeles (California, United States). The system will be approximately 15,000 kilometers in length, avoiding earthquake prone areas in East Asia, and thereby helping to ensure stable connectivity.

When completed in the fourth quarter of 2016 at an approximate cost of US $250 million, the cable system will provide an additional 20Tb/s capacity, connecting Indonesia and the Philippines to the United States with state-of-the-art 100G technology. This capacity will cater to the exponential growth of bandwidth demand between both continents.

“Backed by more than 40 years of experience in constructing over 200,000 kilometers of submarine cable infrastructure, NEC is one of the world’s top vendors of submarine cable systems,” said Mr. Naoki Yoshida, General Manager at NEC’s Submarine Network Division. “The construction of this advanced system enables NEC to capitalize on its experience and contribute to worldwide communications by expanding connectivity and capacity to this increasingly important Trans-Pacific route.”

About Telin

PT. Telekomunikasi Indonesia International (Telin) is a subsidiary of PT. Telekomunikasi Indonesia, tbk, a state-owned telecommunication and network provider. Telin focuses as an international carrier services and strategic investment in international telecommunication business as well as serves as Telkom’s business arms in managing and developing its business lines abroad. With mission The World’s Hub for Telecommunication, Information, Media, Edutainment and Services (TIMES), currently Telin owns 8 subsidiaries namely Telin Singapore, Telin Hong-Kong, Telin Timor-Leste with its product called Telkomcel, Telkom Australia, Telin Malaysia, Telkom Macau, Telkom Taiwan, Telkom USA, and a branch in Myanmar. With the synergy of TelkomGroup compiled with reliable networks and infrastructures, enable Telin to provide high quality services that reaches all parts of the world.

For more information, please go to www.telin.co.id.

About Globe Telecom:

Globe Telecom, Inc. is a leading full service telecommunications company in the Philippines, serving the needs of consumers and businesses across an entire suite of products and services including mobile, fixed, broadband, data connections, internet and managed services. Its principals are Ayala Corporation and SingTel who are acknowledged industry leaders in the country and in the region.

For more information, visit www.globe.com.ph. Follow us on Twitter: http://twitter.com/talk2Globe and Facebook: http://facebook.com/GlobePH.

About RTI:

RAM Telecom International, Inc. (RTI) develops global telecom infrastructure and large-scale data connectivity in selected markets. RTI offers neutral services to telecommunications carrier, large multi-national enterprises, content providers, and government entities. RTI is headquartered in San Francisco, California.

For more information, please visit us at www.rticable.com.

About Hawaiian Telecom:

Hawaiian Telcom, headquartered in Honolulu, is Hawai’i’s leading provider of integrated communications, data center and entertainment solutions for business and residential customers. With roots in Hawai’i beginning in 1883, the Company offers a full range of services including voice, video, Internet, data solutions, managed services, data center services including colocation and virtual private cloud, and other cloud-based services, and wireless supported by the reach and reliability of its network and Hawai’i’s only 24/7 state-of-the-art network operations center. With employees statewide sharing a commitment to innovation and a passion for delivering superior service, Hawaiian Telcom provides an Always OnSM customer experience.

For more information, visit www.hawaiiantel.com.

About GTA:

GTA provides complete communications services in Guam. These include local and long-distance telephone service, wireless, DSL internet access, advanced digital television, or IPTV, and carrier-class data circuits. The company also operates a data center in Guam for offering business data storage and managed wide-area networking. Based in Tamuning, Guam, GTA is privately owned and locally managed.

About GTI Corporation:

GTI Corporation is doing business as GTI Telecom in the State of California. GTI is a wholly owned subsidiary of GTI Business Holdings, Inc., who in turn is a wholly owned subsidiary of Globe Telecom, Inc. GTI was granted a 214 license by the US Federal Communications Commission on February 2010 that authorizes GTI to engage in both wireless resale and facilities-based carrier services in the USA.

For more information, visit www.globemobile.us.

About Telkom USA:

Telekomunikasi Indonesia International (USA), Inc. (Telkom USA) was established on 11thDecember 2013. Located in California and becomes subsidiary with 100% of its shares owned by PT Telekomunikasi Indonesia International (Telin). Telkom USA performs telecommunications products, telecommunications services, Information Technology (IT), Information technology products and information technology services business.

About NEC Corporation:

NEC Corporation is a leader in the integration of IT and network technologies that benefit businesses and people around the world. By providing a combination of products and solutions that cross utilize the company’s experience and global resources, NEC’s advanced technologies meet the complex and ever-changing needs of its customers. NEC brings more than 100 years of expertise in technological innovation to empower people, businesses and society.

For more information, visit NEC at http://www.nec.com.

Of Great Historical, Artistic and Religious Importance – a Unique Byzantine Gold Medallion to be Auctioned by Roma Numismatics Ltd of Mayfair, London

LONDON, Aug. 29, 2014 /PRNewswire/ —

Ancient artefact expected to bring GBP800,000+ in Roma Numismatics’ Sept. 28 auction; on display at 20 Hanover Square, Sept. 1-27. 

A unique and highly important Byzantine gold medallion is expected to fetch GBP800,000+ when it is offered at auction in September by London-based auctioneer Roma Numismatics Ltd. It is among 1,200 superb ancient Greek, Roman and Byzantine coins that are being sold in the firm’s autumn auction. The medallion was struck as part of the grand imperial wedding celebrations for the princess Charito, daughter of the emperor Tiberius II Constantine, to Germanus, the supreme commander of the Byzantine armies, on or around Christmas Day in 583 AD. It weighs over 100 grams, and is one of the very largest gold medallions known to have survived antiquity.

(Photo: http://photos.prnewswire.com/prnh/20140828/703399)

This grand imperial medallion depicts a remarkable series of illustrations from the story of the life of Christ as related by early Christian texts, of which some have no peer or parallel in surviving Byzantine precious metal art. The front features a highly detailed portrayal of the Annunciation, in which the Angel Gabriel delivers his message to Mary that she shall conceive the son of God. It also shows two smaller scenes of the Visitation and the Nativity. The whole of the reverse is dedicated to an image of Christ’s Ascension to Heaven as his disciples look on. It is believed that this medallion preserves the earliest surviving images of the Annunciation and Ascension in gold.

The medallion is comparable only to the famous specimen in the Dumbarton Oaks Museum (Washington D.C., USA) with which it shares a great many similarities, and a lesser example currently residing in the Christian Schmidt Collection (Munich, Germany). All three appear to have been the work of the same imperial artisan and were produced within a very short time-span.

Richard Beale, director of auctioneer Roma Numismatics, said: “This incredible piece is tremendously significant, not only from a historical perspective, but also because of the rich religious symbolism woven into its design. The scenes as portrayed here became the standard model for all subsequent Byzantine and Orthodox depictions of these key moments from the life of Christ. It is thus of immense importance within the fields of both Byzantine and early Christian art.”

Richard Beale, info@romanumismatics.com, +44-(0)20-3178-2874

Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS

— No overall statistically significant increased risk of bladder cancer in patients ever exposed to pioglitazone in a completed 10-year epidemiological study

OSAKA, Japan, Aug. 29, 2014 /PRNewswire/ — Takeda Pharmaceutical Company Limited (“Takeda”) today announced the completion of the post-marketing commitment and submissions of data from a 10-year epidemiology study to regulatory authorities including the United States (U.S.) Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Japanese Ministry of Health, Labour, and Welfare (MHLW) / the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for pioglitazone containing medicines, including ACTOS (pioglitazone HCl).1,2 This study was a 10-year epidemiology study, conducted by the University of Pennsylvania and Division of Research at Kaiser Permanente Northern California (KPNC), and was designed to investigate whether patients exposed to pioglitazone were at an increased risk of bladder cancer.1 Findings demonstrate that there is no statistically significant increased risk of bladder cancer among patients ever exposed to pioglitazone.2

The primary analysis found no association between the use of pioglitazone and the risk of bladder cancer.2 Additionally, no association was found between the risk of bladder cancer and the duration of pioglitazone use, increased cumulative dose of pioglitazone or the time since initiating pioglitazone.

In the five-year interim analysis published in Diabetes Care, a statistically significant increased risk among patients who used pioglitazone for two or more years was observed.1 However, the 10-year final analysis did not show any statistically significant findings of increased risk of bladder cancer with long term use of pioglitazone.2 The data will be shared with additional regulatory authorities in accordance with local requirements around the world, and final results will be submitted for publication in 2014.   

“The completion of this long-term study is a milestone in the history of pioglitazone,” said Tom Harris, head, global regulatory affairs, Takeda. “The results of the study provide reassurance with regard to the use of pioglitazone and the risk of bladder cancer and further support the positive benefit risk profile of the product.”

About Pioglitazone

Pioglitazone is approved as an agent to treat patients with Type 2 diabetes mellitus in more than ­­­100 countries world-wide. More than 27,000 subjects have been included in clinical trials, and globally the total patient-years of exposure since first launch (1999) is estimated to be in excess of more than 29 million. Pioglitazone as a treatment of Type 2 diabetes mellitus at the recommended doses provides a valuable treatment option, and has a well established safety profile. The benefits of good glycemic control associated with Type 2 diabetes mellitus outweigh the risks associated with therapy which are appropriately communicated and managed by the current product labelling.

Pioglitazone is a thiazolidinedione for the treatment of Type 2 diabetes in adults as an adjunct to diet and exercise.

Unlike many oral antidiabetic drugs, pioglitazone is not an insulin secretagogue. Pioglitazone is an agonist for peroxisome proliferator-activated receptor-gamma (PPARγ). PPAR receptors are found in tissues important for insulin action such as adipose tissue, skeletal muscle, and liver. Activation of PPARγ nuclear receptors modulates the transcription of a number of insulin responsive genes involved in the control of glucose and lipid metabolism. Therefore, pioglitazone is a medication that depends on the presence of insulin for its mechanism of action, and it decreases insulin resistance in muscle and the liver, resulting in increased insulin-dependent glucose disposal as well as decreased hepatic glucose output.

Clinical studies demonstrate that pioglitazone improves insulin sensitivity in insulin-resistant patients. Pioglitazone enhances cellular responsiveness to insulin, increases insulin-dependent glucose disposal and improves hepatic sensitivity to insulin. In patients with Type 2 diabetes, the decreased insulin resistance produced by pioglitazone results in lower plasma glucose concentrations, lower plasma insulin concentrations, and lower HbA1c values. In controlled clinical trials, pioglitazone had an additive effect on glycemic control when used in combination with sulfonylurea, metformin, or insulin.

Important Safety Information

Contraindications

Initiation of ACTOS is contraindicated in patients with NYHA Class III or IV heart failure.

ACTOS is contraindicated in patients with known hypersensitivity to pioglitazone or any of its excipients so as to avoid inducing a potentially serious hypersensitivity reaction.

Warnings and Precautions

Fluid retention and cardiac failure: Thiazolidinediones, including ACTOS, can cause dose-dependent fluid retention, which may exacerbate or precipitate heart failure. After initiation of ACTOS, and after dose increases, monitor patients carefully for signs and symptoms of heart failure (e.g., excessive, rapid weight gain, dyspnea, and/or edema). If heart failure develops, discontinuation of ACTOS must be considered. ACTOS should be used with caution in patients with cardiac dysfunction whose physical activity is markedly limited. Combination use with insulin may increase risk.

Hepatic effects: Post-marketing reports of hepatitis and hepatic dysfunction have been received. Very rarely these reports have involved hepatic failure, with and without a fatal outcome, although causality has not been established. Obtain liver tests before starting ACTOS and periodically thereafter. Pioglitazone therapy should not be initiated in patients with increased liver enzyme levels (ALT> 2.5x upper limit of normal) or with any other evidence of liver disease. Existing pioglitazone therapy should be discontinued if ALT levels are persistently higher than 3x the upper limit of normal, and symptoms suggesting hepatic dysfunction should cause the liver enzymes to be checked. Pending the results of laboratory investigations, the decision as to whether pioglitazone therapy should continue must be based on clinical judgment; in the presence of jaundice, drug therapy should be discontinued.

Weight gain: Weight gain was observed in clinical trials and has been seen in post-marketing experience with pioglitazone, so patient weight should be closely monitored.

Fractures: An increased incidence of bone fracture has been noted in female patients.

Bladder cancer: Some data suggest there may be an increased risk of bladder cancer in ACTOS users and also that the risk increases with duration of use. Do not use ACTOS in patients with active bladder cancer. Use caution when using in patients with a prior history of bladder cancer. Tell patients to promptly report any sign of hematuria or other symptoms such as dysuria or urinary urgency as these may be due to bladder cancer.

Hypoglycemia: When ACTOS is used with insulin, a sulfonylurea or other oral hypoglycemic agents, hypoglycemia may occur.

Ovulation: Ovulation in premenopausal anovulatory women or women with polycystic ovarian syndrome may occur with ACTOS.

Macular edema: Post-marketing reports of new-onset or worsening diabetic macular edema with decreased visual acuity have been reported with thiazolidinediones, including pioglitazone. Physicians should consider the possibility of macular edema if a patient reports decreased visual activity.

Drug interactions: Use of ACTOS with CYP2C8 inducers or strong inhibitors may require dose adjustment.

Please refer to the Summary of Product Characteristics (SmPC) for ACTOS before prescribing.

ACTOS should be used according to the indication, posology and method of administration described in the SmPC.

Please consult with your local regulatory agency for approved labeling in your country.

About Type 2 diabetes

  • In 2013, 382 million people worldwide were living with Type 2 diabetes. By 2035 this number is expected to rise to 592 million.3
  • In 2013, the number of people with diabetes in Europe was estimated to be 56 million.4
  • The number of Type 2 diabetes patients is increasing in every country.3
  • In 2013, one in 10 deaths in adults in Europe was attributed to diabetes, representing over 600,000 people.3
  • Estimates indicate that more than EUR 108 billion* was spent on healthcare due to diabetes in the European region in 2013, accounting for over one-quarter of global healthcare expenditures due to diabetes.3
  • Because of the increasingly complex nature of this disease, all patients require treatment to be individualized to their needs.5 Each patient responds differently to medications, and healthcare providers often must combine multiple treatment options to help patients manage their disease.

*Based on conversion of USD 147 billion,3 where 1 EUR = 1.36035 USD as of 21 July 2014.

About Takeda’s Diabetes Business

Takeda’s heritage in diabetes globally includes significant contributions towards scientific discovery and exchange, starting with the discovery of the thiazolidinedione (TZD) pioglitazone, and developments of other fixed-dose combinations. The company’s strong, diverse diabetes portfolio and available medications mark important milestones in Takeda’s ongoing commitment to advancing patient care and helping to meet the individual needs of this growing patient population.

About Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine.

Additional information about Takeda is available through its corporate website, www.takeda.com.

Contact:

Elissa J. Johnsen
+1-224-554-3185  
elissa.johnsen@takeda.com

References

[1] Lewis, JD., Ferrara, A., Peng, T., et al. The Risk of Bladder Cancer Among Diabetic Patients Treated with Pioglitazone: Interim Report of a Longitudinal Cohort Study. Diabetes Care 24, April 2011 34:4 923-929.

[2] Takeda Data on File. 2014. 

[3] International Diabetes Federation. IDF Atlas, sixth edition. Last accessed July 10, 2014. Available at: http://www.idf.org/diabetesatlas.

[4] International Diabetes Federation. Diabetes: Facts and figures. Last accessed July 10, 2014. Available at: http://www.idf.org/worlddiabetesday/toolkit/gp/facts-figures.

[5] Inzucchi SE, Bergenstal RM et al. Management of Hyperglycaemia in Type 2 Diabetes: A Patient-Centred Approach. Diabetes Care. 2012:35: (6):1364-1379.

Frost & Sullivan: Who’s Benefitting from Retail Product Protection?

– Product protection plans boost revenue and customer loyalty for retailers

MOUNTAIN VIEW, Calif., Aug. 29, 2014 /PRNewswire/ — The adoption of retail product protection plans continues to increase in the United States. Frost & Sullivan estimates the total US retail product protection market size to be approximately $8-10 billion across consumer electronics, home appliances, jewelry, sporting goods, furniture, and other product categories. Strong support of leading retailers, coupled with greater consumer awareness of the need and utility of retail product protection plans, continues to drive demand for retail product protection solutions.

A recent analysis from Frost & Sullivan, Retail Product Protection Plans in the United States: A Market and Competitive Overview, presents an overview of the retail product protection plan market in the United States. The insight analyzes the key elements of advanced retail product protection plans and outlines the benefits for both consumers and retailers. Additionally, Frost & Sullivan evaluates the industry’s most progressive retail product protection products from market leading providers.

For complimentary access to more information on this research, please visit: http://bit.ly/1vSWYMC

“Issues with electronics or appliances requiring repairs or replacement are prevalent in today’s marketplace; our research indicates that roughly 1 in 5 retail customers that purchase an electronics device or a major appliance are likely to have a problem with the product within the first 12 months,” said Brent Iadarola, Frost & Sullivan Research Director. “Protection plans provide a defined path for consumers to resolve their product issues by receiving assistance to repair or replace the covered product.”

Initially positioned as a value-added service (VAS), retail product protection plans have evolved as integral tools for retailers to enhance customer loyalty and generate incremental category sales. Consumers are attracted by the multiple benefits protection plans have to offer such as single source solution, quality care, and protection from unexpected costs. Hence, a well-structured retail product protection plan can help retailers improve customer satisfaction, increase store visits and ultimately revenue.

The emergence of ‘connected’ consumer electronics and appliances has also materialized as an important growth driver for the retail product protection industry. As products become ‘smarter’, post-sales technical support will be crucial to help customers troubleshoot device issues, reduce product returns, and optimize the overall customer experience.

Retailers should seek providers with progressive roadmaps that offer integrated and complete solutions to ensure a seamless customer experience. Furthermore, retailers should consider parameters such as product capabilities, customer support and service innovation, sales enablement and marketing capabilities, when selecting a retail product protection partner.

“While on the surface all product protection plans seem very much alike, they are clear differentiators when it comes to servicing customers,” noted Iadarola. “Retailers are encouraged to conduct a detailed analysis of the various retail product protection providers in order to select the right partner to help meet their growth objectives.”

Retail Product Protection Plans in the United States: A Market and Competitive Review is part of the Mobile & Wireless Communications (http://www.wireless.frost.com) Growth Partnership Service Program. Frost & Sullivan’s related studies include:  Next Generation Mobile Protection Market Insight, An Insight into the U.S. Mobile Device Logistics Markets; Mobile Handset Protection, A Win-Win for Carriers and Consumers. All research included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion

Join Us:           Join our community

Subscribe:       Newsletter on “the next big thing”

Register:         Gain access to visionary innovation

Retail Product Protection Plans in the United States: A Market and Competitive Overview

Contact:
Clarissa Castaneda
Corporate Communications – North America
P: 210.477.8481
E: clarissa.castaneda@frost.com

Twitter: @Stratecast / @FS_ITVision
LinkedIn: Future Growth Opportunities in ICT
Facebook: Frost & Sullivan

http://www.frost.com

Sasol, EDM Inaugurate New Gas-to-Power Plant in Mozambique

RESSANO GARCIA, Mozambique, Aug. 29, 2014 /PRNewswire/ —

Earlier today, the President of the Republic of Mozambique, Armando Guebuza, and the Mozambican Minister of Energy, Salvador Namburete, joined the chairman of the Mozambican state power utility, Electridade de Mozambique (EDM), Augusto Fernando de Sousa and the President and CEO of Sasol, David Constable, at the inauguration of Central Termica de Ressano Garcia (CTRG).

The CTRG power plant, which is a partnership between EDM (51%) and Sasol (49%), represents Mozambique’s first permanent large-scale gas-to-power facility in Ressano Garcia, which is on the border between Mozambique and South Africa.

Natural gas will be supplied to the new power plant from the Sasol-operated central processing facility (CPF) in Temane in the Inhambane province. Together with its partners, Sasol has expended approximately US$3 billion in capital investments, which include the development and expansion of the CPF and natural gas fields in Southern Mozambique, the construction of a cross-border pipeline, and the completion of the CTRG gas-to-power project.

The 175MW gas-fired power plant will supply electricity to more than two million Mozambicans – this equates to 23% of the country’s current demand. The Mozambican economy is one of the fastest growing on the African continent, and is seeing electricity demand increasing by approximately 14% annually.

The opening of the CTRG power facility comes as Sasol celebrates its 10th anniversary of developing the Temane and Pande stranded gas fields in Mozambique, through strong in-country partnerships and its technical expertise. The company’s investments over the past decade have contributed to the creation of a favourable investment climate for Mozambique, while establishing an exploration and natural gas production sector in the region. These investments also serve to support economic growth and development in both Mozambique and South Africa.

Sasol President and CEO, David Constable said, “By working together with our Mozambican and South African partners, we are well-placed to unlock the ultimate potential of Mozambique’s hydrocarbon resources in an integrated and sustainable manner, which will benefit not only the country but the broader region.”

EDM Chairman Augusto Fernando de Sousa commented, “Despite Mozambique’s extensive hydrocarbon resources, EDM is currently experiencing an electricity deficit which necessitates importing power. CTRG will help enhance the country’s energy self-sufficiency and will also help to diversify our energy base.”

The gas-fired power plant is expected to reach beneficial operation in October this year.

About Sasol:

Committed to excellence in all we do, Sasol is an international integrated energy and chemical company that leverages the talent and expertise of our more than 33 000 people working in 37 countries. We develop and commercialise technologies, and build and operate world-scale facilities to produce a range of product streams, including liquid fuels, high-value chemicals and low-carbon electricity.

While remaining committed to our home-base of South Africa, Sasol is expanding internationally based on a unique value proposition.

Issued by: 

Alex Anderson, Head of Group Media Relations
Direct telephone +27-(11)441-3295
Mobile +27-(0)71-600-9605
alex.anderson@sasol.com

CAIDE Looks into the Future: New App from Merz Pharmaceuticals Assesses the Risk of Getting Dementia Within the Next 20 Years

FRANKFURT AM MAIN, Germany, Aug. 29, 2014 /PRNewswire/ — The CAIDE Dementia Risk App from Merz Pharmaceuticals is available free of charge for people from 40 to 65 to calculate their individual risk for getting dementia within the next two decades. Using a traffic light color scheme, the App can also help physicians discuss preventive measures with patients at risk.

The new “CAIDE Dementia Risk App (Cardiovascular risk factors, Aging and Incidence of DEmentia) has been developed in collaboration with Karolinska Institutet in Stockholm and is available in the App Store for a free download. The CAIDE App may be used on an iPhone or iPad and comes in two versions: one for physicians and one for individuals. It is available in five languages: German, French, Spanish, Russian, and English as default.

CAIDE supports prevention of dementia 

After entering gender, date of birth, height and weight, cholesterol level, blood pressure, physical activity and years of education the App calculates the risk of getting dementia within the next 20 years. If the risk is in the normal range an orange bar appears. The bar is green if the risk is lower and red if it is higher than average. Then the physician should discuss preventive lifestyle interventions.

Professor Miia Kivipelto who has done the research (1,2) on which the App is based says: “The biggest risk factor for developing dementia is advanced age. Large epidemiological studies have demonstrated that what is good for the heart is good for the brain – in other words, a healthy lifestyle with physical activity, low blood cholesterol levels, not being obese, and having normal blood pressure at midlife protects not only against cardiac disease, but also against dementia.”

More information about Merz on http://www.merz.com.

  1. Kivipelto M et al.; Lancet Neurol 2006;5:735-41
  2. Sindi et al. Poster presented at the 13th Geneva /Springfield Symposium, March 2014

Pressekontakt:
Merz Pharmaceuticals GmbH
Dr. Elisabeth Calov
Tel: +49-(0)69-1503-8428
E-mail: elisabeth.calov@merz.de